Clinical Trials
35 trialsCabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
M.D. Anderson Cancer Center
LIBRETTO-321
Eli Lilly and Company
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
National Cancer Institute (NCI)
QUILT-3.006 for Recurrent Medullary Thyroid Cancer
NantCell, Inc.
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
National Cancer Institute (NCI)
Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications
University College, London
A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
Columbia University
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
M.D. Anderson Cancer Center
Nintedanib(BIBF1120) in Thyroid Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
National Cancer Institute (NCI)
An Initial Study of Lithium in Patients With Medullary Thyroid Cancer
University of Wisconsin, Madison
Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
University of Pennsylvania
Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
Bayer
Thalidomide in Treating Patients With Thyroid Cancer
University of Kentucky
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Massachusetts General Hospital
Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
University of Washington
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
A Study To Assess ZD6474 (ZACTIMAâ„¢) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Sanofi
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer
Federico II University
Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer
Yonsei University
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
National Cancer Institute (NCI)
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Delcath Systems Inc.
A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
Amgen
Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
National Cancer Institute (NCI)
SUMMIT
Eanm Research Ltd
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
Vanderbilt-Ingram Cancer Center
DOPMET
Assistance Publique - Hôpitaux de Paris